Genzyme — Proxy Contest (June 2010)
9 slides from Genzyme's proxy contest presentation, Jun 3, 2010
Slide 1: Responses to RiskMetrics Group Questions
Responses to RiskMetrics Group Questions 1 Changes to Relational Investors Settlement Agreement Third Party Observations Regarding Icahn’s Conflicts The Consent Decree: A Research Analyst’s Perspective Relationships Between Mr. Icahn and His Nominees Observations and Responses to Mr. Icahn’s Present
Slide 2: Changes to Relational Investors Settlement Agreement
2 As a gesture of good faith between Relational Investors and Genzyme, the amended language in the cooperation agreement sets the Termination Date as follows: “Termination Date shall be the earlier of (a) the Company’s 2013 Annual Meeting of Shareholders, or (b) the first date following June 16, 201
Slide 3: Third Party Observations Regarding Icahn's Conflicts
2. Third Party Observations Regarding Icahn’s Conflicts 3 BernsteinResearch, Geoffrey Porges, 1-Jun-2010 “[I]nvestors do not appear convinced that Icahn's interests and those of other independent investors are aligned. Icahn, by virtue of their substantial cross holding in Biogen Idec and recently e
Slide 4: The Consent Decree: A Research Analyst's Perspective
4 Given More FDA Enforcement Action as Obama Administration Has Taken An Aggressive Enforcement Posture – Genzyme CD Likely Best Case Scenario [Emphasis Added] As way of background, FDA Commissioner Hamburg has ushered in a new era of FDA enforcement of the Food, Drug, and Cosmetic Act. Hamburg has
Slide 5: Relationships Between Mr. Icahn and His Nominees
5 Dr. Burakoff Donor In Feb-04, Mr. Icahn made a $25 million gift to Mount Sinai Medical Center, which supported research at the Mount Sinai School of Medicine. This resulted in the establishment of The Icahn Medical Institute Mr. Icahn is currently a Trustee of the Medical Center Dr. Burakoff is Pr
Slide 6: Genzyme's Responses to, and Relationship with, the FDA
6 Genzyme’s Responses to, and Relationship with, the FDA Icahn suggests that Genzyme “blatantly ignored” the FDA and “if any real progress is to be made... we must immediately change the Board” (p.3) As we previously noted throughout our 25-May presentation (including p. 7-8, 18-20, 33-34), Genzyme
Slide 7: Disclosure of Form 483's and Warning Letters
7 Disclosure of Form 483’s and Warning Letters Icahn repeatedly cites to “undisclosed Form 483’s” (p.35, 40) and of the Feb-09 “undisclosed warning letter” (p.36, 41) However, it is well-established case law that a 483 does not require disclosure because they are (i) not a final determination and (i
Slide 8: Disclosure Regarding Icahn's Relationships with His Nominees
8 Disclosure Regarding Icahn’s Relationships with His Nominees Icahn cites the extensive qualifications of his nominees, and holds out Burakoff as an independent candidate (p.52) However, Icahn does not mention his cash payments to Mulligan and Burakoff, or Icahn’s role as trustee and donor of Mt. S
Slide 9: Important Information
Important Information 9 On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company’s definitive proxy statement and other proxy materials befo